Contrasting Ensysce Biosciences (NASDAQ:ENSC) and CannAmerica Brands (OTCMKTS:CNNXF)

CannAmerica Brands (OTCMKTS:CNNXF) and Ensysce Biosciences (NASDAQ:ENSC) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Insider & Institutional Ownership

5.6% of Ensysce Biosciences shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for CannAmerica Brands and Ensysce Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CannAmerica Brands	0	0	0	0	0.00
Ensysce Biosciences	1	0	0	0	1.00

Given CannAmerica Brands’ higher possible upside, equities research analysts plainly believe CannAmerica Brands is more favorable than Ensysce Biosciences.

Profitability

This table compares CannAmerica Brands and Ensysce Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CannAmerica Brands	N/A	N/A	N/A
Ensysce Biosciences	-250.39%	-766.45%	-256.59%

Earnings & Valuation

This table compares CannAmerica Brands and Ensysce Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CannAmerica Brands	N/A	N/A	N/A	N/A	N/A
Ensysce Biosciences	$5.07 million	1.33	-$10.18 million	($3.35)	-0.13

CannAmerica Brands has higher earnings, but lower revenue than Ensysce Biosciences.

About CannAmerica Brands

CannAmerica Brands Corp. owns a portfolio of brands of medical cannabis and recreational cannabis products. The company primarily builds and maximizes the value of its brands by promoting, marketing, and licensing brands through various distribution channels, including dispensaries, wholesalers, and distributors in the states of Colorado, Nevada, Oklahoma, and Massachusetts. It offers cannabis infused gummy products, disposable vape pens, distillate droppers, and shatter and wax concentrate products under the CannAmerica brand. The company is headquartered in Vancouver, Canada.

About Ensysce Biosciences

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.